On March 12, 2024 Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, reported an expanded manufacturing agreement with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution (Press release, Ratio Therapeutics, MAR 12, 2024, View Source [SID1234641054]). The collaboration aims to significantly accelerate the development and commercialization of Ratio’s pipeline of next-generation radiotherapies, representing a critical component in advancing Ratio’s fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to partner with PharmaLogic, an industry-leading CDMO with over 15 years of experience in radiopharmaceutical manufacturing and supply chain solutions" said Dr. Matthias Friebe, Chief Technology Officer of Ratio. "With advanced facilities, substantial capacity, and an impressive track record of quality and compliance, PharmaLogic has demonstrated their ability to reliably produce highly complex radiopharmaceutical products. Their expertise in sophisticated technologies such as accelerated radiochemistry and automation will ensure efficient, scalable production of our novel pipeline therapies to meet future commercial demands. This collaboration represents a major step towards Ratio Therapeutics’ mission of discovering and rapidly transitioning innovative radiopharmaceuticals to the clinic, aiming to transform treatment paradigms and improve patient outcomes."

"We are honored to collaborate with Ratio Therapeutics and support their pipeline of precision-targeted radiotherapies," said D. Scott Holbrook, Chief Strategy Officer and General Manager at PharmaLogic. "Ratio is at the forefront of developing radiopharmaceutical solutions that have the potential to significantly improve patient outcomes. By leveraging our combined expertise and manufacturing capabilities, we aim to make these cutting-edge therapies readily available to patients in need."

Ratio, in collaboration with Lantheus and PharmaLogic, is currently conducting a Phase I trial evaluating the efficacy of a novel FAP-targeted imaging biomarker, copper-64[Cu-64]-labeled LNTH-1363S (formerly RTX-1363S) for PET imaging in adult healthy volunteers. The company also recently announced a $50M Series B financing which will significantly drive the clinical advancement of Ratio’s first FAP-targeted therapeutic candidate into clinical trials this year.

On March 11, 2024 GenScript reported its 2023 Annual Results Presentation (Presentation, GenScript, MAR 11, 2024, https://www.genscript.com/gsfiles/IPO/2023%20Annual%20Results.pdf?1153641870 [SID1234644733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 11, 2024 Modulus Discovery, Inc (Headquartered in Chiyoda-ku, Tokyo; CEO S. Roy Kimura) reported that, effective March 11, 2024, the Company has changed its name to Alivexis, Inc (Press release, Modulus Discovery, MAR 11, 2024, View Source,Modulus%20Discovery%2C%20Inc.%20to%20Change%20Its%20Name%20to%20Alivexis%2C,its%20name%20to%20Alivexis%2C%20Inc. [SID1234644086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details】
●　New company name: Alivexis, Inc.（URL：View Source;
●　Date of change: March 11, 2024
*Please note that this change is limited to the company name; there will be no changes to the address or representatives.
*Concurrent with this name change, our subsidiary, Modulus Discovery, Inc. (Headquarters: 1 Broadway, 14th Floor, Cambridge, MA 02142; CEO S. Roy Kimura), will also be changing its name to Alivexis, Inc.

【Purpose of the Company Name Change】
Since its establishment in August 2016, we have committed to delivering groundbreaking pharmaceuticals efficiently to patients suffering from cancer, chronic immune and inflammatory diseases, and rare diseases, along with their families. Our mission has been to integrate insights into core biology, cutting-edge drug discovery platforms, and a global network-based research system to advance our unique portfolio of small molecule drug discovery projects and various research and development collaborations. Aiming to fulfill this social mission, we have been operating as a network-based drug discovery company, led by a team with extensive experience in drug discovery and computational science research within pharmaceutical and biotechnology companies, with bases in Tokyo and Boston.

As of March 2024, our strengths – (1) insights into core biology crucial to life and diseases, (2) a unique drug discovery platform, and (3) an attractive drug research pipeline – have been crystalized as clinical development candidates in three lead projects, with several more projects making significant progress into late-stage of lead optimization. Considering the substantial changes in the internal and external business environment since the company’s inception, we have changed the name of our company and its subsidiaries to "Alivexis" with the aim of further clarifying our social mission and focus areas for future business development.

【Origin of the new Company Name】
The new name "Alivexis" is a blend of "alive," signifying "life, living," "synthesis," representing "the combination of various elements to form a larger entity or concept," and "exis," meaning "to arise, to emerge." It was selected to reflect our hope that vibrant, healthy, and happy lives will emerge from our drug discovery platform and research and development activities.

【Our Mission Reinforced by Our New Identity】
Alivexis is dedicated to fostering healthier and more fulfilling lives by integrating cutting-edge drug discovery platforms, profound understanding of disease biology, and agile global business operations.

【CEO S. Roy Kimura’s Comments】
"I am thrilled to announce our new corporate name, Alivexis, which signifies the vitality of life emerging from our deep commitment and passion to deliver much needed medicines for patients and their families afflicted by various diseases. Over the last 6 years I have had the pleasure to be part of an exceptionally hard-working and talented team to accomplish what some initially thought impossible — rapidly discovering multiple novel high-value drug candidates starting from zero resources by leveraging our cutting-edge drug discovery platform. Our new name marks the beginning of the next stage in our evolution, growing from a platform-based drug discovery firm to a therapeutics driven company with a powerful platform and multiple programs nearing clinical trials. We continue to be excited about our mission to discover and deliver new medicines for patients in need around the globe.

On March 11, 2024 Assertio Holdings, a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 (Press release, Assertio Holdings, MAR 11, 2024, View Source [SID1234643722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 11, 2024 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024 (Press release, Adicet Bio, MAR 11, 2024, View Source [SID1234641042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follows:

Date: Tuesday, March 26, 2024
Time: 10:30 a.m. ET

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.